skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
Sponsored by:

Global Generics & Biosimilars Awards Entry Deadline 19 August 2022

The Global Generics and Biosimilars Awards celebrate the greatest achievements and innovations across the development, authorisation, marketing and distribution of global off-patent pharmaceuticals. Co-locating with CPhI Worldwide in Frankfurt, these illustrious awards provide a unique opportunity for the industry to come together to discuss future opportunities and challenges and shine a light on the companies and individuals driving positive change. Winners will be recognised across 14 categories, including Biosimilar Initiative of the Year, Leader of the Year, API Supplier of the Year and Business Development of the Year.

KEY DETAILS
  • Entries close 19 August 2022
  • Ceremony 2 November 2022
  • Free to enter
  • Frankfurt Marriott Hotel, Germany

The Global Generics and Biosimilars Awards are free to enter. The closing date for entries is 19 August 2022, and the qualifying period for submissions is 1 July 2021 - 31 July 2022. The judging process will take place over the summer. The finalists will be announced in September and the winners revealed at the Awards on 2 November 2022.

THE GLOBAL GENERICS & BIOSIMILARS AWARDS categories 2022

Download All

Open to any company that generates at least a third, or at least US $250 million, of its annual sales from generics or biosimilars.

WHAT YOU NEED TO KNOW

Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Open to any company that generates at least a third, or at least US $250 million, of its annual sales from generics or biosimilars. Qualification for a region is dependent on the headquarters (not tax domicile) of a company’s generics and/or biosimilars business. There are awards for the following regions: Americas / EMEA / Asia-Pacific.

WHAT YOU NEED TO KNOW

Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Open to any company which has acquired another company that is active in generics and/or biosimilars, or has acquired a portfolio of generic and/or biosimilar products.

WHAT YOU NEED TO KNOW

Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Open to any member of the senior management team of a firm within the generics or biosimilars industries. Judges will want to see how the entered leaders have best applied company values within the business environment – achieving measured and sustainable growth, driving improved performance, delivering shareholder value, implementing robust strategies, engaging staff, demonstrating market knowledge and true customer insight.

WHAT YOU NEED TO KNOW

Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Entries in this category could include known molecules that are repurposed for new indications, reformulated in a way that adds value for patients, put together in innovative combinations, or which feature added-value packaging or delivery methods.

WHAT YOU NEED TO KNOW

Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Open to any generics and/or biosimilars alliance, joint venture, distribution agreement, licensing deal or similar that does not involve the acquisition of another company or a portfolio of products.

WHAT YOU NEED TO KNOW

Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Open to any company supplying off-patent active pharmaceutical ingredients (APIs) or Intermediates.

WHAT YOU NEED TO KNOW

Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Entries may relate to any biosimilar currently marketed, approved or in clinical development, sales and marketing initiatives, distribution agreements or other initiatives aimed at increasing biosimilar usage.

WHAT YOU NEED TO KNOW

Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Awarded to identify excellence in the regulatory sphere. This could include innovative approaches to obtaining marketing authorisations, regulatory milestones for individual companies, or developments that represent a wider breakthrough for the global generics and/or biosimilars industries.

WHAT YOU NEED TO KNOW

Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Humanitarian charity International Health Partners (IHP) has partnered with Generics Bulletin to create this Award. Entries could include: company approach to CSR, implementation, engagement plans, raining & education programmes, compulsory licensing and humanitarian aid donations.

WHAT YOU NEED TO KNOW

Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

This category allows generics, biosimilars and value-added medicines firms as well as their partnering law firms to highlight outstanding results from their approach to intellectual property and their legal strategy. This could include notable litigation results allowing a competitive advantage or early launch; inventive ways of getting around or invalidating intellectual property; obtaining intellectual property to protect their own products or processes; or ways in which legal strategies or IP approaches from different global jurisdictions have been used as a template elsewhere, showing the benefits of a coordinated international IP strategy.

WHAT YOU NEED TO KNOW

Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Awarded to recognise outstanding achievements by firms or individuals that work alongside generics and biosimilars manufacturers and suppliers. These could include logistics providers, contract-research organisations, contract manufacturers, law firms and consultants.

WHAT YOU NEED TO KNOW

Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

The Judges

Enter Now

Ready to submit your entry to the Global Generics & Biosimilars Awards 2022? Enter today to be in with a chance of winning

Enter Now

Want to sponsor an award?

Sponsorship of the Global Generics & Biosimilars Awards provides exclusive opportunities, targeted branding, thought leadership and lead generation. Seize the opportunity to come together, to educate and engage with the companies who matter to you most.

Sponsor Opportunities

BOOK A TABLE

Looking to attend the Global Generics & Biosimilars Awards? Book your table today for the awards!

BOOK YOUR TABLE

Headline Sponsor

IQVIA™ is a leading global provider of information, innovative technology solutions and contract research services focused on using data and science to help healthcare clients find better solutions for their patients. Formed through the merger of IMS Health and Quintiles, IQVIA offers a broad range of solutions that harness advances in healthcare information, technology, analytics and human ingenuity to drive healthcare forward.

IQVIA enables companies to rethink approaches to clinical development and commercialization, innovate with confidence as well as accelerate meaningful healthcare outcomes. IQVIA has approximately 55,000 employees in more than 100 countries, all committed to making the potential of Human Data Science a reality. IQVIA’s approach to Human Data Science is powered by the IQVIA CORE™, driving unique actionable insights at the intersection of big data, advanced technology and analytics with extensive industry knowledge. To learn more, visit www.iqvia.com

our 2022 sponsors

Insud Pharma

Since its foundation in 2009, Pharmacloud has steadily built up its reputation as a provider of specialist advice and consultancy to both the pharma industry and financial investors. We offer a number of services, with a particular focus on commercial due diligence on off-patent products. However, we also work with big pharma companies on generic defence strategies, as well as with emerging pharma companies seeking to assess the potential market for their value-added generic products or biosimilars.

The research side of our business is currently being built up, starting from the base of our well-regarded industry blog. Look out for the first in our series of in-depth reports beginning in 2015.

Pharmawise is a specialist pharmaceutical consultancy. We give our clients strategic, commercial and scientific advice and support through our international network of industry experts. With deep expertise in your sector, we can help you tackle your most complex and specialised challenges; develop your strategic and operational plans; and improve the efficiency of your operations.

SanaClis is a full-service Global CRO with a fully integrated clinical supply chain, thereby offering a comprehensive range of end-to-end services for clinical trials. SanaClis was founded in 2000 by seasoned industry experts, all of whom have had executive level positions in leading pharma companies and large global CROs.

SanaClis has vast experience of successfully running studies for various sized sponsors, ranging from virtual biotech’s through to top ten pharma companies, both in terms of its CRO services and Clinical supply services. Every project is a fundamental priority for the SanaClis, irrespective of the size or scope. SanaClis believes that every company and professional should receive an extremely high level of quality and clinical excellence applied to its projects. SanaClis prides itself upon its esteemed track record of successfully delivering various projects on time and on budget, ensuring quality, expertise and responsiveness resonates throughout the entire project duration.

Whilst SanaClis offers the provisions of our services across all therapeutic areas and geographic locations (entire Europe, UK, Asia and USA), SanaClis has a substantial and unique expertise in Central and Eastern European countries, regions of which provide an abundance of advantages, from high recruitment rates through to high quality of data. In addition to being a full service CRO, SanaClis is one of the very few service providers with an extensive range of in-house logistics and clinical supply capabilities. SanaClis has a portfolio of privately owned GMP and GDP certified storage and distribution depots, strategically located across the EU, US and further Eastern European countries.

CRO services include:

  • Project management
  • Regulatory
  • Monitoring
  • Data management and biostatistics
  • Medical writing
  • Pharmacovigilance

Further in-house supply chain services include:

  • QP services (EU QP release)
  • customs brokerage
  • warehousing and distribution (at all required temp conditions, ambient, cold, frozen, cryo etc)
  • sourcing of clinical trial materials (including ancillaries, PPE), comparator, generics and rescue medication sourcing.

This unique and fully comprehensive service offering allows SanaClis to streamline the entire project from end-to-end, thereby creating cost efficiencies, whilst maintaining a high level of quality at all times

STADA is a leading manufacturer of high-quality pharmaceuticals. With a long-standing heritage rooted in pharmacies, we are perceived as a reliable and trustworthy partner for more than 125 years. With our products we help people protect and regain a dignified and able life. With our proven Generics, we ensure that everyday health remains affordable. To our employees, we offer an attractive working environment in which they can develop personally.

West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With approximately 10,000 team members across 50 sites worldwide, West helps support our customers by delivering over 45 billion components and devices each year.

Headquartered in Exton, Pennsylvania, West in its fiscal year 2021 generated $2.83 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com.

our 2022 supporters

In communities around the world affected by chronic poverty, conflict or disasters, easily treatable diseases can mean chronic pain, poor quality of life or even a death sentence. International Health Partners (IHP) was founded in 2003 with a vision to radically enhance access to medicine to the world’s most vulnerable people. IHP enable targeted donations of medicines from a network of over 60 healthcare companies across Europe, and coordinate the safe and responsible supply of these to disaster hit and vulnerable communities across the world. IHP are the only organisation working to this model in the UK. In the last three years IHP have sent over 8.2 million treatments, with a value of over £34.5 million.

International Generic and Biosimilar Medicines Association

PREVIOUS Global Generics & Biosimilars Award CEREMONIES

Want to view previous Global Generics & Biosimilars Awards? Take a look back at our previous Awards and winners.

2021
GLOBAL GENERICS & BIOSIMILARS AWARDS 2021

November 10, 2021

2020
GLOBAL GENERICS & BIOSIMILARS AWARDS 2020

Virtual ceremony November 3, 2020

2019
GLOBAL GENERICS & BIOSIMILARS AWARDS 2019

November 5, 2019

got a question about the awards?

Please enter your name
Please enter your email
Please enter your valid email
Please enter your question
Please accept the terms & conditions
Senior Events Manager

jo.kirkpatrick@informa.com